Gideon Blumenthal was named vice president for Global Oncology Regulatory Affairs at Merck.
He is a former deputy director of the FDA Oncology Center of Excellence.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
